So, Who are the appropriate individuals that should consider genetic counseling and genetic testing?
|
|
- Alicia Gallagher
- 5 years ago
- Views:
Transcription
1 Hello, I m Banu Arun, Professor of Breast Medical Oncology and Co-Director of Clinical Cancer Genetics at the University of Texas MD Anderson Cancer Center. Today I will be discussing with you Hereditary Breast and Ovarian Cancer Syndrome: Management of Breast Cancer Risk. Upon completion of this lecture, participants will be able to describe breast cancer risk management option including screening, chemoprevention, and surgery for individuals with a BRCA1 or BRCA2 mutation; understand the benefits and limitations of current chemoprevention options, and ongoing studies for novel chemoprevention agents; recognize complex cases; and consider referral to high-risk programs for participation in screening protocols and clinical studies. This table illustrates risk factors for breast cancer. As seen here, the highest risk is conferred by having deleterious mutations in the BRCA1 or BRCA2 gene. Individuals with this mutation have a up to ten-fold increased risk or a lifetime risk of up to 80% of developing breast cancer. But the second group that increases breast cancer risk are individuals with a known pre-malignant breast disease, such as ductal carcinoma in situ, lobular carcinoma in situ, or atypical hyperplasias. These individuals have --- can have a up to four-fold increased risk of developing breast cancer. Then there are other risk factors that are related to endocrine factors or diet and exercise-related factors, such as early menarche, no pregnancies or later pregnancies, hormone replacement therapy. As you can see here, the increased risk is in a two-fold risk level. I would like to now talk a little bit about BRCA1 and BRCA2 mutations and the risk it confers. As you can see her --- here, the first example is population risk. A woman s lifetime risk to develop breast cancer by age 70 is anywhere between 10 to 11 percent. However, individuals who have a deleterious mutation in the BRCA1 or BRCA2 gene have a[n] up to 80 percent risk of breast cancer or up to tenfold increased risk. Having BRCA1 and BRCA2 mutations also increases risk of second and other cancers. For examples, these women are at a higher risk, ten-fold increased risk, to develop ovarian cancer, with a lifetime risk being at least 16 percent, even up to 40 percent. And, very important for a patient who already has one breast cancer, if that individual has a deleterious mutation in the BRCA1 or BRCA2 risk, her risk to develop contralateral breast cancer, so a second primary cancer, is up to 64 percent, based on two prospective trials, by age 70. So, Who are the appropriate individuals that should consider genetic counseling and genetic testing? This slide lists for us the red flags where we should pay closer attention to the family history and consider referring patients or individuals for genetic counseling and then potentially testing. For example, an individual with a personal history of breast cancer diagnosed before age 50 should be considered for genetic counseling. Individuals with especially a certain subtype of breast cancer such as having triple negative or ER/PR-
2 and HER2-negative cancer, even without family history, should be considered for genetic counseling if they were diagnosed before age 50 or even before age 60. If there are --- there s a family history of multiple cases of early onset breast cancer, again, those individuals should be looked at closer. A family history should be taken and a referral for genetic counseling should be made. If there is ovarian cancer within the family history of breast or ovarian cancer at any age, should be considered for counseling. If a woman has a breast and ovarian cancer, her likelihood of having a BRCA mutation is more than 80 percent. This woman is certainly a candidate to consider genetic counseling and testing. Individuals with bilateral breast cancer, especially if the first breast cancer was diagnosed at a younger age, Ashkenazi Jewish heritage, and also a family history of male breast cancer should alert us to look at the family history a little bit closer and make a referral for genetic counseling and potentially subsequent testing. There is also more and more evidence that individuals, especially younger women with a history of ductal carcinoma in situ, even in the absence of invasive cancer with or without family, should be considered for genetic counseling and testing. The American Society of Clinical Oncology Guidelines recommend a cancer predisposition testing should be offered when there is a high likelihood of a positive test and if there --- if we can adequately interpret the test results, and if the test results will influence medical management. That means for unaffected individuals, so the individuals who do not have a diagnosis of cancer, risk management options. And for the affected individuals, that means individuals who already have a diagnosis of cancer, for example breast or ovarian cancer, treatment decisions. When we discuss risk management options we like to divide the --- our approaches into two different categories. One risk management option category is the ones that are affecting the unaffected individuals, the individuals without cancer. And then the other group is how to manage individuals who already developed breast cancer and how the genetic information could be used in those individuals. I would like to start our approach [with], how to discuss risk management options with unaffected individuals. The categories we discuss include surveillance, prevention with a drug, chemoprevention, and preventive surgery, such as prophylactic mastectomy and prophylactic oophorectomies. A few questions: Question number one, Breast cancer screening for a woman with a BRCA mutation should include monthly self-breast exams, semiannual clinical breast exams, and A) Annual mammograms, B) Annual breast MRIs, C) Annual mammograms and annual breast MRIs,. D) Annual mammograms and annual ultrasounds. The answer is C. Individuals with a deleterious BRCA mutation are candidates to undergo annual mammograms plus annual breast MRIs. The data supporting this comes from several studies that are either retrospective or prospective, as illustrated in this table. Several studies evaluated in high risk individuals either with known or unknown BRCA mutations, the value of adding MRI to standard screening, such as mammogram and some studies, ultrasounds and clinical breast
3 exams. And what all of these studies concluded is that adding an MRI to breast screening is more accurate, more sensitive, and more informative. And, indeed, in 2007, the American Cancer Society guidelines included breast MRI screening for individuals at high risk. And these guidelines are now in the NCCN screening recommendation guidelines for women with deleterious BRCA mutations. The guidelines include self-breast exams, training and education starting at age 18, clinical breast exams every six to 12 months starting at age 25, annual mammogram and breast MRI screening starting at age 25, or individualized based on earliest age of onset in family, and discuss options for risk reducing mastectomy on a case-by-case basis. And I will come back to the surgical intervention in a little while. Recommended risk reduction salpingo-oophorectomy should be ideally done between ages 35 and 40, and upon completion of childbearing, individualized based on earliest age of onset of ovarian cancer in the family. For those individuals who have decided not to undergo risk reducing salpingo-oophorectomy consider trans --- transvaginal ultrasound and C-125 levels every six months starting at age 35, or five to 10 years before the earliest age of ovarian cancer in the family. And also consider chemoprevention options that I will be also discussing in a minute. In men with BRCA mutations, self-breast exam training and education is recommended to start at age 35, clinical breast exams every six to 12 months starting at age 35, and also consider baseline mammograms at age 40, annual mammogram if gynecomastia or parenchymal glandular breast density on baseline study, and adhere to screening guidelines for prostate cancer. So now I would to switch gears and talk a little bit about chemoprevention for these individuals. This table summarizes for us the prospectively-run Phase III large breast cancer prevention trials. As you know, there are three positive, actually four positive new trials to date. The very first trial was done in high-risk women under the NSABP P-1 trial. That compared tamoxifen to placebo in 13,000 women and there was a 50 percent reduction in the risk of developing invasive breast cancer. The second larger trial was done in the UK, the IBIS-I trial, that also compared tamoxifen to placebo in 7,000 women, and there was about 30 percent risk reduction in invasive breast cancers. Then, the NSABP --- NSABP P-2 launched a second trial comparing now tamoxifen, the winner of the P-1 trial, to raloxifene, another selective estrogen receptor modulator, in high-risk but postmenopausal women, in about 19,000 women, and both agents were able to reduce the incidence of breast cancer. However, the benefit to reduce invasive breast cancer was about 20 percent more for tamoxifen over raloxifene. And finally, very recently in 2011, a Canadian NCIC study reported on the benefit of exemestane versus placebo, showing a more than 65 percent risk reduction in the incidence of invasive cancer in postmenopausal, high-risk women who took exemestane versus placebo.
4 So, our second question set, Tamoxifen is likely [to] be more effective for: A) BRCA1 mutation carriers, B) BRCA2 mutation carriers, C) Tamoxifen is equally effective for BRCA1 and BRCA2 mutation carriers, D) Tamoxifen should not be used for mutation carriers. The answer is D. Tamoxifen should not be used for mutation carriers because none of the studies actually looked prospectively in these mutation carriers so we do not have any prospective data. A few pearls about selective estrogen receptor modulators used in clinical practice as chemopreventive agents. As we know, acceptance for these agents is low. It s less than 20, it s less than percent, most probably because of the side effects that are not acceptable to an individual who is otherwise in good health. Increased risk of endometrial cancer, thromboembolic events, and most importantly, menopausal symptoms such as hot flashes, cognitive function problems, and weight gain. More importantly, these agents do not prevent the development of estrogen receptor-negative breast cancer. And about 70 percent of the BRCA1-associated breast cancer are estrogen receptor negative. Therefore, research in this area done by us and many others include to --- to try to find agents and targets that are effective in estrogen receptor-negative breast cancer development, such as a nonsteroidal anti-inflammatory drugs, COX-2 inhibitors, retinoids, small molecular tyrosine kinase inhibitors, and NF-kappa B inhibitors, and many others. There are currently smaller Phase II prevention studies going on at our institution, but also [at] other institutions, trying to evaluate potential chemopreventive effect of agents. Using a FNA model where we obtain tissue before and after treatment for three to six months to evaluate changes in the tissue, we and others have completed Phase II prevention studies using different agents such as anastrozole, celecoxib, vitamin A, Targretin, and some others that are either currently ongoing or pending. The idea is, again, to try to prevent ER-negative breast cancer but also find agents that can also prevent --- that also have less side effects and are not as toxic as tamoxifen so that the acceptance among high-risk women is high. There are also ongoing large Phase III trials, such as the IBIS-II trial, that is randomizing high-risk women in Europe to placebo versus anastrozole. There is a study that is called an Italian study in BRCA mutation carriers, evaluating letrozole versus placebo, an aromatase inhibitor. The NSABP-B35 has conducted a study in ductal carcinoma in situ anastrozole versus tamoxifen. And finally, a aromatase inhibitor, letrozole versus raloxifene study was going to happen but that study is at this point on hold. As you can see, though, these --- all of these studies include agents that only prevent ER-positive breast cancer and these agents are only indicated in postmenopausal women. So we really do not have anything at this time to prevent ER-negative breast cancer patients, especially ER-negative breast cancer especially in younger or premenopausal women. Question number 3, Prophylactic mastectomy reduces breast cancer risk by: A) 90 to 95 percent, B) Reduces risk by 100 percent, C) Reduce breast cancer risk by 75 to 80
5 percent, D) Should not be used for women with BRCA mutations. The correct answer is A. Prophylactic bilateral mastectomy reduces breast cancer risk by 90 to 95 percent in individuals who have a deleterious BRCA1 or BRCA2 mutation based on prospective trials. Mastectomies can be done either as simple mastect --- simple total mastectomies or subcutaneous mastectomy, even though the thought is that a total mastectomy appears to be more effective, and, as mentioned, in prospective trials, have been shown to reduce breast cancer risk by more than 90 percent. As I have mentioned individuals at incr --- with a BRCA1 or BRCA2 deleterious mutation are also at increased risk to develop ovarian cancer. Therefore, oophorectomy is also discussed with these individuals to reduce the risk of ovarian cancer. However, if done in the premenopausal setting, these individuals also benefit in terms of breast cancer. Prospective studies have shown that if women undergo oophorectomies in the premenopausal setting, their breast cancer risk is actually decreased by about 50 to 53 percent. However, some studies have shown that the benefit is only seen in BRCA2 carriers, even though this data needs to be approached carefully as the --- in the subgroup analyses, the number of BRCA2 mutation carriers was very low. But, overall, there is a benefit in terms of breast cancer risk reduction when patients also undergo oophorectomies. Now, I would like to switch gears a little bit and discuss with you very briefly the management options for individuals who already have developed breast cancer, who underwent genetic testing and were found to have a BRCA1 or BRCA2 mutation. It is important for us nowadays, because it might have treatment implications. For example, in terms of surgeries, if we have a patient with Stage I breast cancer, a young woman with a BRCA mutation, she might be eligible to undergo segmental mastectomy and have radiation therapy. However, if she has a BRCA mutation, because of the increased risk of contralateral breast cancer, she might opt to do bilateral mastectomies. So, therefore, she has these choices that she can discuss with her surgeon. If this individual has ER --- estrogen receptor-positive breast cancer and undergoes the oophorectomy, she might be a candidate actually to be treated adjuvantly with an aromatase inhibitor instead of tamoxifen. And, very excitingly, recently new targeted agents have been developed that for the first time ever can target cancer that are associated for --- with hereditary cancer. For example, the PARP inhibitors have been studied in Phase I and Phase II, and [are] now being studied in Phase III clinical trials for BRCA1 and 2-associated breast as well as BRCA1 and 2-associated ovarian cancer. And, furthermore, once we identify a mutation in the person with cancer, we know what the mutation is and we can do predictive testing in individuals in that family, especially first degree relatives, to identify if the relatives carry the mutation, and discuss with them risk management options that I just summarized for you. So, in summary, we really need to evaluate family history very carefully in patients with or without cancer. It is ideal if we perform the genetic testing first on the patient who has cancer and then once we identify a mutation, we should offer predictive testing to unaffected family members because if they are positive, they truly would benefit from risk reduction approaches. We should discuss screening, surgery, and
6 chemoprevention, what we know and what we don t know in this field. And, very importantly, refer for clinical trials and registries. Many research questions remain unans --- unanswered and we all need to work together. I would like to thank you for your attention and would like to encourage you please to give us feedback. Thank you.
Breast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
More informationOBJECTIVES 8/25/2017. An attempt to organize the chaos
High Risk for Breast Cancer and Genetics: Who? What? Where? When? An attempt to organize the chaos Presented at Winds of Change Conference November 3, 2017 by Carol Hager, MSN, CRNP and Allison Haener,
More informationHBOC Syndrome A review of BRCA 1/2 testing, Cancer Risk Assessment, Counseling and Beyond.
HBOC Syndrome A review of BRCA 1/2 testing, Cancer Risk Assessment, Counseling and Beyond. Conni Murphy, ARNP Cancer Risk Assessment and Genetics Program Jupiter Medical Center Learning Objectives Identify
More informationBreast Cancer Risk Assessment and Prevention
Breast Cancer Risk Assessment and Prevention Katherine B. Lee, MD, FACP October 4, 2017 STATISTICS More than 252,000 cases of breast cancer will be diagnosed this year alone. About 40,000 women will die
More informationSo how much of breast and ovarian cancer is hereditary? A). 5 to 10 percent. B). 20 to 30 percent. C). 50 percent. Or D). 65 to 70 percent.
Welcome. My name is Amanda Brandt. I am one of the Cancer Genetic Counselors at the University of Texas MD Anderson Cancer Center. Today, we are going to be discussing how to identify patients at high
More informationThis includes bone loss, endometrial cancer, and vasomotor symptoms.
Hello and welcome. My name is Chad Barnett. I m a Clinical Pharmacy Specialist in the Division of Pharmacy at the University of Texas, MD Anderson Cancer Center and I m very pleased today to be able to
More informationFactors Associated with Early Versus Late Development of Breast and Ovarian Cancer in BRCA1 and BRCA2 Positive Women
Texas Medical Center Library DigitalCommons@The Texas Medical Center UT GSBS Dissertations and Theses (Open Access) Graduate School of Biomedical Sciences 5-2010 Factors Associated with Early Versus Late
More informationFAQ-Protocol 3. BRCA mutation carrier guidelines Frequently asked questions
ULast updated: 09/02/2015 Protocol 3 BRCA mutation carrier guidelines Frequently asked questions UQ: How accurate are the remaining lifetime and 5 year breast cancer risks in the table? These figures are
More informationUtilization of BRCA Testing. Breast and Ovarian Cancer in Texas
Utilization of BRCA Testing in Older Ode Women with Breast and Ovarian Cancer in Texas Ana M. Rodriguez, MD Assistant Professor Department of Obstetrics and Gynecology University of Texas Medical Branch
More informationRisk Assessment, Genetics, and Prevention
Risk Assessment, Genetics, and Prevention Katherine D. Crew, MD MS Director, Clinical Breast Cancer Prevention Program Columbia University Medical Center 1 Outline Breast cancer risk factors Hereditary
More informationHereditary breast cancer who to refer to a cancer genetics clinic and how to counsel patients with
Hereditary breast cancer who to refer to a cancer genetics clinic and how to counsel patients with positive and negative results? SAMO Workshop Luzern 3./4.10.2014 Dr. med. Barbara Bolliger TumorTumor-
More informationIncreased Risk of Breast Cancer: Screening and Prevention. Elizabeth Pritchard, MD 4/5/2017
Increased Risk of Breast Cancer: Screening and Prevention Elizabeth Pritchard, MD 4/5/2017 No disclosures Defining Risk Risk Factors Modifiable Lifestyle obesity physical activity alcohol consumption breast
More informationHereditary Breast and Ovarian Cancer Rebecca Sutphen, MD, FACMG
Hereditary Breast and Ovarian Cancer 2015 Rebecca Sutphen, MD, FACMG Among a consecutive series of 11,159 women requesting BRCA testing over one year, 3874 responded to a mailed survey. Most respondents
More informationSo, now, that we have reviewed some basics of cancer genetics I will provide an overview of some common syndromes.
Hello. My name is Maureen Mork and I m a Certified Genetic Counselor in the Clinical Cancer Genetics Program at The University of Texas MD Anderson Cancer Center. I ll be lecturing today on the Cancer
More informationMANAGEMENT OF HIGH RISK BREAST PATIENTS DR PAMELA THOMPSON BREAST PHYSICIAN, FSH
MANAGEMENT OF HIGH RISK BREAST PATIENTS DR PAMELA THOMPSON BREAST PHYSICIAN, FSH HIGH RISK MANAGEMENT OBJECTIVES Be alert to FHx Breast and/or Ovarian cancer Know how to perform a risk assessment Be aware
More informationPrimary Care Approach to Genetic Cancer Syndromes
Primary Care Approach to Genetic Cancer Syndromes Jason M. Goldman, MD, FACP FAU School of Medicine Syndromes Hereditary Breast and Ovarian Cancer (HBOC) Hereditary Nonpolyposis Colorectal Cancer (HNPCC)
More informationJill Stopfer, MS, CGC Abramson Cancer Center University of Pennsylvania
Jill Stopfer, MS, CGC Abramson Cancer Center University of Pennsylvania Aging Family history Early menarche Late menopause Nulliparity Estrogen / Progesterone use after menopause More than two alcoholic
More informationCancer Genetics Unit Patient Information
Chemoprevention for women at an increased risk of familial breast cancer Cancer Genetics Unit Patient Information What is chemoprevention? Chemoprevention describes drugs that are used to reduce the risk
More informationClinical guideline Published: 25 June 2013 nice.org.uk/guidance/cg164
Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer Clinical guideline Published: 25 June 2013 nice.org.uk/guidance/cg164
More informationW3C Life Sciences: Clinical Observations Interoperability: EMR + Clinical Trials Use-case for EMR + Clinical Trials Interoperability
W3C Life Sciences: Clinical Observations Interoperability: EMR + Clinical Trials Use-case for EMR + Clinical Trials Interoperability Background: The key issue is to investigate whether some of the data
More informationManagement of BRCA Positive Breast Cancer. Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH
Management of BRCA Positive Breast Cancer Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH The number of American women who have lost their lives to breast cancer outstrips the total number
More informationBreast cancer is the most frequently
Charmaine Kim-Sing, MBChB, FRCPC, Lorna Weir, MD, FRCPC, and Urve Kuusk, MD, FRCPC Breast cancer risk management for moderaterisk and high-risk women An accurate assessment of breast cancer risk can help
More informationBreast Cancer Basics. Clinical Oncology for Public Health Professionals. Ben Ho Park, MD, PhD
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationEligibility criteria for prophylactic treatment allowance
Eligibility criteria for prophylactic treatment allowance Southern Cross will only pay the prophylactic treatment allowance for the following healthcare services when the applicable eligibility criteria
More informationThis information explains the advice about familial breast cancer (breast cancer in the family) that is set out in NICE guideline CG164.
Familial breast cancer (breast cancer in the family) Information for the public Published: 1 June 2013 nice.org.uk About this information NICE guidelines provide advice on the care and support that should
More informationScreening for Genes for Hereditary Breast and Ovarian Cancer in Jewish Women
Screening for Genes for Hereditary Breast and Ovarian Cancer in Jewish Women Background About 5% of women in Canada with breast cancer and about 12% of women with ovarian cancer, are born with an inherited
More informationBRCA mutation carrier patient: How to manage?
BRCA mutation carrier patient: How to manage? Clinical Case Presentation Katarzyna Sosińska-Mielcarek Department of Oncology and Radiotherapy University Clinical Center Gdansk, Poland esmo.org DISCLOSURE
More informationSpectrum of Care Options for Women at High Risk for Breast and Ovarian Cancer
Spectrum of Care Options for Women at High Risk for Breast and Ovarian Cancer Sheryl G.A. Gabram, MD, MBA, FACS Professor of Surgery, Emory University Director, High Risk Assessment Program Winship Cancer
More informationpatient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015
patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015 BRCA1 and BRCA2 Mutations Cancer is a complex disease thought to be caused by several different factors. A few types of cancer
More informationEffective Health Care Program
Comparative Effectiveness Review Number 17 Effective Health Care Program Comparative Effectiveness of Medications To Reduce Risk of Primary Breast Cancer in Women Executive Summary Background Breast cancer
More informationRALOXIFENE Generic Brand HICL GCN Exception/Other RALOXIFENE EVISTA Is the request for the prevention (risk reduction) of breast cancer?
Generic Brand HICL GCN Exception/Other RALOXIFENE EVISTA 16917 GUIDELINES FOR USE 1. Is the request for the prevention (risk reduction) of breast cancer? If yes, continue to #2. If no, approve by HICL
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationEvaluation & Management of PowerPoint Cover Title. the High Risk Population. High Risk Clinic
Evaluation & Management of PowerPoint Cover Title the High Risk Population High Risk Clinic Subtitle Joanna Would Springman, Go Here PA-C Assessment Genetics Known genetic mutation Family history with
More informationPatient Education. Breast Cancer Prevention. Cancer Center
Patient Education Breast cancer affects one in nine women in the US by the time they reach their 80 s. It is the result of several mutations or alterations in the genes found in the DNA of normal breast
More informationProphylactic Mastectomy
Prophylactic Mastectomy Policy Number: Original Effective Date: MM.06.010 01/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO 08/24/2012 Section: Surgery Place(s) of Service: Inpatient I.
More information--- or not, and do we need to come up with newer strategies for ovarian cancer screening.
My name is Dr. Karen Lu and I am a Professor of Gynecologic Oncology at the University of Texas MD Anderson Cancer Center. I also serve as Co-Medical Director for Clinical Cancer Genetics. I m going to
More informationBreast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment?
Breast Cancer Breast Cancer Excess Estrogen Exposure Nulliparity or late pregnancy + Early menarche + Late menopause + Cystic ovarian disease + External estrogens exposure + Breast Cancer Excess Estrogen
More informationDoes Cancer Run in Your Family?
Does Cancer Run in Your Family? A Patient s Guide to Hereditary Breast and Ovarian Cancer Syndrome What is Hereditary Cancer? Most cancers occur in people who do not have a strong family history of that
More informationBreast Cancer Prevention Studies. Key Points. Breast cancer prevention studies are clinical trials (research studies conducted with
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Breast Cancer Prevention
More informationKaren degenevieve MSN, FNP, BC
Karen degenevieve MSN, FNP, BC Become more comfortable treating common breast complaints. Discuss recent controversial screening recommendations. Discuss oral medications used in breast cancer prevention
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, for early-stage triple-negative breast cancer, 740 742 in older early-stage breast cancer patients, 790 795 anti-her2-directed
More informationHighlights: 2008 San Antonio Breast Cancer Symposium
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/conference-coverage/highlights-2008-san-antonio-breast-cancersymposium/4099/
More informationMastectomy For Treatment, For Prevention, For Prophylaxis Not as Simple as Following Data
Mastectomy For Treatment, For Prevention, For Prophylaxis Not as Simple as Following Data Nathalie Johnson, MD FACS Medical Director, Legacy Cancer Institute and Breast Health Centers Objectives Understand
More informationWomen s Health: Breast Cancer Screening. K. Rast, MD and E. McNany, MD
Women s Health: Breast Cancer Screening K. Rast, MD and E. McNany, MD 2013 2017 Update: Who? How? When? Cases and Practice Questions Question 1 A 40 year old female comes to your office for a well woman
More informationManagement of women at high risk of breast cancer
Follow the link from the online version of this article to obtain certified continuing medical education credits Management of women at high risk of breast cancer Anne C Armstrong, 1 Gareth D Evans 2 3
More informationBRCA1 & BRCA2 GeneHealth UK
BRCA1 & BRCA2 GeneHealth UK BRCA1 & BRCA2 What is hereditary breast cancer? Cancer is unfortunately very common, with 1 in 2 people developing cancer at some point in their lifetime. Breast cancer occurs
More informationProphylactic Mastectomy
Prophylactic Mastectomy Policy Number: Original Effective Date: MM.06.010 01/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO 07/22/2011 Section: Surgery Place(s) of Service: Inpatient I.
More informationUnderstanding Your Genetic Test Result. Positive for a Deleterious Mutation or Suspected Deleterious
Understanding Your Genetic Test Result Positive for a Deleterious Mutation or Suspected Deleterious This workbook is designed to help you understand the results of your genetic test and is best reviewed
More informationpatient education Fact Sheet
patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations OCTOBER 2017 BRCA1 and BRCA2 Mutations Cancer is caused by several different factors. A few types of cancer run in families. These types are
More informationUnderstanding Your Genetic Test Result. Positive for a Deleterious Mutation or Suspected Deleterious
Understanding Your Genetic Test Result Positive for a Deleterious Mutation or Suspected Deleterious This workbook is designed to help you understand the results of your genetic test and is best reviewed
More informationProphylactic Mastectomy
Prophylactic Mastectomy Policy Number: Original Effective Date: MM.06.010 01/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 12/01/2013 Section: Surgery Place(s) of Service:
More informationChemo-endocrine prevention of breast cancer
Chemo-endocrine prevention of breast cancer Andrea DeCensi, MD Division of Medical Oncology Ospedali Galliera, Genova; Division of Cancer Prevention and Genetics, European Institute of Oncology, Milano;
More informationBreast Cancer Risk Assessment: Genetics, Risk Models, and Screening. Amie Hass, MSN, ARNP, FNP-BC Hall-Perrine Cancer Center
Breast Cancer Risk Assessment: Genetics, Risk Models, and Screening Amie Hass, MSN, ARNP, FNP-BC Hall-Perrine Cancer Center Disclosure- I DO NOT HAVE any relevant financial interest with any entity producing,
More informationProphylactic Mastectomy
Prophylactic Mastectomy Policy Number: Original Effective Date: MM.06.010 01/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 09/01/2015 Section: Surgery Place(s) of Service:
More informationA Slow Starvation: Adjuvant Endocrine Therapy of Breast Cancer
A Slow Starvation: Adjuvant Endocrine Therapy of Breast Cancer Dr. Susan Ellard Surgical Oncology Update October 24, 2009 Disclosure slide Participant in various meetings or advisory boards sponsored by
More informationThe impact of hereditary breast and ovarian cancer (HBOC) syndrome testing on patient management and your practice
The impact of hereditary breast and ovarian cancer (HBOC) syndrome testing on patient management and your practice Use BRACAnalysis as a guide in your medical and surgical management BRACAnalysis testing
More informationBreast Cancer Prevention for the Population at Large
Breast Cancer Prevention for the Population at Large Jack Cuzick Centre for Cancer Prevention Wolfson Institute of Preventive Medicine St Bartholomew s Medical School Queen Mary University of London London,
More informationNo Disclosures. 9/20/16 WHERE DO WE GO FROM HERE? MANAGING PREVIVORSHIP AND SURVIVORSHIP NICOLE CENTERS PREVIVOR AND SURVIVOR
WHERE DO WE GO FROM HERE? MANAGING PREVIVORSHIP AND SURVIVORSHIP Aileen Caceres, MD, MPH, FACOG Nicole Centers, RN, OCN, CBCN, CN-BN, CPN No Disclosures. NICOLE CENTERS PREVIVOR AND SURVIVOR "Cancer previvors"
More informationBreast Cancer Risk Reduction
Clinical in Oncology Breast Cancer Risk Reduction V.1.2008 Continue www.nccn.org Panel Members * Therese B. Bevers, MD/Chair Þ The University of Texas M.D. Anderson Cancer Center Mary Gemignani, MD Memorial
More informationAn Update on Breast Cancer Screening and Prevention.
Thomas Jefferson University Jefferson Digital Commons Department of Family & Community Medicine Faculty Papers Department of Family & Community Medicine 6-2014 An Update on Breast Cancer Screening and
More informationTissue Breast Density
Tissue Breast Density Reporting breast density within the letter to the patient is now mandated by VA law. Therefore, this website has been established by Peninsula Radiological Associates (PRA), the radiologists
More informationThe Genetics of Breast and Ovarian Cancer Prof. Piri L. Welcsh
The Genetics of Breast Piri L. Welcsh, PhD Research Assistant Professor University of Washington School of Medicine Division of Medical Genetics 1 Genetics of cancer All cancers arise from genetic and
More informationCancer Conversations
Cancer Conversations Announcer: Welcome to Cancer Conversations, a podcast series from Dana-Farber Cancer Institute. In this Episode from July 2014, Dr. Huma Rana, Clinical Director of Dana-Farber s Center
More informationThe Study of Tamoxifen and Raloxifene (STAR): Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s The Study of Tamoxifen
More informationBreast Cancer Risk and Prevention
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Breast Cancer Risk and Prevention Breast Cancer Risk and Prevention Versions 2003 2012: Schmutzler with Albert / Blohmer /
More informationAssessment and Management of Genetic Predisposition to Breast Cancer. Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18
Assessment and Management of Genetic Predisposition to Breast Cancer Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18 Overview The role of the Cancer Genetics team NICE guidelines for Familial Breast
More informationBREAST CANCER BREAST CANCER
BREAST CANCER George Raptis, M.D., M.B.A Division of Medical Oncology & Hematology College of Physicians & Surgeons Columbia University BREAST CANCER Epidemiology - Commonest cancer in women - About 235,000
More informationBreast Cancer: Selected Topics for the Primary Care Clinician
Breast Cancer: Selected Topics for the Primary Care Clinician Leah Karliner, MD MAS October 2009 Primary Care Medicine: Principles and Practice OUTLINE Incidence and Mortality Risk Factors and Risk Reduction/Prevention
More informationBRCAplus. genetic testing for hereditary breast cancer
BRCAplus genetic testing for hereditary breast cancer Developed in collaboration with Fox Chase Cancer Center and the Arcadia University Genetic Counseling Program. Causes of Hereditary Breast Cancer familial
More informationMelissa Hartman, DO Women s Health Orlando VA Medical Center
Melissa Hartman, DO Women s Health Orlando VA Medical Center Most common non-skin cancer and Second deadliest cancer in women Majority are diagnosed by abnormal screening study An approach to breast cancer
More informationUpdates in Cancer Genetics & Genomics
Updates in Cancer Genetics & Genomics Jennifer R. Klemp, PhD, MPH, MA Associate Professor of Medicine, Division of Clinical Oncology Director, Cancer Survivorship Co-Program Leader, Cancer Prevention and
More informationPOSITIVE DELETERIOUS MUTATION
Understanding Your Genetic Test Result Positive for a Deleterious or Suspected Deleterious POSITIVE DELETERIOUS MUTATION This workbook is designed to help you understand the results of your genetic test
More informationBreast Cancer Risk and Prevention
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Breast Cancer Risk and Prevention Breast Cancer Risk and Prevention Version 2003: Kiechle / Schmutzler Versions 2004 2011:
More informationOriginal Policy Date
MP 7.01.06 Prophylactic Mastectomy Medical Policy Section Surgery Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to Medical Policy Index
More informationChristine Garcia, MD 1, Liisa Lyon, MS 2, Ramey D. Littell, MD 1 and C. Bethan Powell, MD 1
American College of Medical Genetics and Genomics Comparison of risk management strategies between women positive for a BRCA variant of unknown significance and women with known BRCA deleterious mutations
More informationImportance of Family History in Gynecologic Cancer Prevention. Objectives. Genetic Counselors. Angela Thompson, MS, CGC
Importance of Family History in Gynecologic Cancer Prevention Angela Thompson, MS, CGC Genetic Counselor Froedtert & The Medical College of Wisconsin Objectives Introduce role of genetic counselor Discuss
More informationGeneHealth BRCA 1&2_ qxp_Layout 1 21/02/ :44 Page 3 BRCA1 & BRCA2 GeneHealth UK
GeneHealth BRCA 1&2_8.2.17.qxp_Layout 1 21/02/2017 16:44 Page 3 BRCA1 & BRCA2 GeneHealth UK GeneHealth BRCA 1&2_8.2.17.qxp_Layout 1 21/02/2017 16:44 Page 4 BRCA1 & BRCA2 What is hereditary breast cancer?
More informationHereditary Breast and Ovarian Cancer (HBOC) Information for individuals and families
Hereditary Breast and Ovarian Cancer (HBOC) Information for individuals and families What is Hereditary Breast and Ovarian Cancer (HBOC)? Hereditary Breast and Ovarian Cancer is a genetic condition which
More informationBreast Cancer: Current Approaches to Diagnosis and Treatment
Breast Cancer: Current Approaches to Diagnosis and Treatment Barbara L. Smith, MD, Ph.D. Massachusetts General Hospital Division of Surgical Oncology No Disclosures Incidence of Breast Cancer USA 2018
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationAsk the Experts Obstetrics & Gynecology
1 Management of the Adnexal Mass James H. Liu, MD, and Kristine M. Zanotti, MD June 2011 Volume 117 Issue 6 Pages 1413 28 Click Here to Read the Full Article Questions written by: Rini Banerjee Ratan,
More informationAN EXAMINATION OF CANADIAN FAMILY PHYSICIANS KNOWLEDGE AND PRACTICE PATTERNS REGARDING BREAST CANCER PREVENTION
AN EXAMINATION OF CANADIAN FAMILY PHYSICIANS KNOWLEDGE AND PRACTICE PATTERNS REGARDING BREAST CANCER PREVENTION by Mary-Kathryn Tighe A thesis submitted to the Department of Community Health and Epidemiology
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationCase 1. BREAST CANCER From Diagnosis to Treatment: The Role of Primary Care
BREAST CANCER From Diagnosis to Treatment: The Role of Primary Care Leah Karliner, MD MAS University of California San Francisco Primary Care Medicine Update 2009 April 2009 Case 1 AR, a 60 year old African
More informationInheriting Breast Cancer: Genetic counseling for the BRCA 1 and BRCA 2 genes. Erin Kern. University of Kansas School of Nursing
Inheriting Breast Cancer: Genetic counseling for the BRCA 1 and BRCA 2 genes Erin Kern University of Kansas School of Nursing About the author: A resident of Shawnee, Kansas, Erin is a member of Phi Kappa
More informationBREAST CANCER. Dawn Hershman, MD MS. Medicine and Epidemiology Co-Director, Breast Program HICCC Columbia University Medical Center.
BREAST CANCER Dawn Hershman, MD MS Florence Irving Assistant Professor of Medicine and Epidemiology Co-Director, Breast Program HICCC Columbia University Medical Center Background Breast cancer is the
More informationAdvice about familial aspects of breast cancer and epithelial ovarian cancer
Advice about familial aspects of breast cancer and epithelial ovarian cancer a guide for health professionals FEBRUARY 2006 These guidelines contain three parts: 1. Information for health professionals
More informationGenetic Screening Visit
Before your visit In a typical hereditary breast ovarian cancer genetic counsling visit be prepared to answer the following set of questions, please check were applicable. About your self (same questions
More informationBreast Cancer Screening: Changing Philosophies in Educating Women and Teens
Breast Cancer Screening: Changing Philosophies in Educating Women and Teens Courtney Benedict CNM MSN Disclosures Merck Nexplanon trainer Session Objectives Explain the rationale for initiation and frequency
More informationSporadic Cancer - Cancer which occurs by chance. People with sporadic cancer typically do not have relatives with the same type of cancer.
to risk assessment Hereditary Cancer Testing: Is it Right for You? This workbook is designed to help you decide if hereditary cancer testing is right for you and should be reviewed with a trained healthcare
More informationLOBULAR CARCINOMA IN SITU: WHAT DOES IT MEAN? THE SURGEON'S PERSPECTIVE
: WHAT DOES IT MEAN? THE SURGEON'S PERSPECTIVE Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University of Washington Joint Member, Fred Hutchinson Cancer
More informationGermline Genetic Testing for Breast Cancer Risk
Kathmandu, Bir Hospital visit, August 2018 Germline Genetic Testing for Breast Cancer Risk Evidence-based Genetic Screening Rodney J. Scott Demography in New South Wales (total population ~ 7,000,000)
More informationCancer Genomics 101. BCCCP 2015 Annual Meeting
Cancer Genomics 101 BCCCP 2015 Annual Meeting Objectives Identify red flags in a person s personal and family medical history that indicate a potential inherited susceptibility to cancer Develop a systematic
More informationMousa. Israa Ayed. Abdullah AlZibdeh. 0 P a g e
1 Mousa Israa Ayed Abdullah AlZibdeh 0 P a g e Breast pathology The basic histological units of the breast are called lobules, which are composed of glandular epithelial cells (luminal cells) resting on
More informationBreast Cancer Risk Factors 8/3/2014
Breast Cancer Screening: Changing Philosophies in Educating Women and Teens Courtney Benedict CNM MSN Session Objectives Explain the rationale for initiation and frequency of clinical breast exams to clients
More informationA breast lump or thickening that feels different from the surrounding tissue
Breast Cancer Breast cancer is caused by abnormal cells that form in the breast tissue. Breast cancer is the most common cancer affecting South African women 1 in 35 women in South Africa will be diagnosed
More informationHBOC. Jessica M. Salamone, ScM, CGC
HBOC Jessica M. Salamone, ScM, CGC Certified Genetic Counselor Director of the Cancer Risk Assessment & Genetic Counseling Program Elizabeth Wende Breast Care, LLC Elizabeth Wende Breast Care Internationally
More informationBreast Cancer Screening Clinical Practice Guideline. Kaiser Permanente National Breast Cancer Screening Guideline Development Team
NATIONAL CLINICAL PRACTICE GUIDELINE Breast Cancer Screening Clinical Practice Guideline Kaiser Permanente National Breast Cancer Screening Guideline Development Team This guideline is informational only.
More informationESMO SUMMIT MIDDLE EAST 2018
ESMO SUMMIT MIDDLE EAST 2018 Breast Clinical Cases Presentation Hampig Raphael Kourie, MD, MSc, MBioethics Faculty of Medicine, Saint Joseph University of Beirut, Lebanon 6-7 April 2018, Dubai, UAE CONFLICT
More informationInherited Ovarian Cancer Diagnosis and Prevention
Inherited Ovarian Cancer Diagnosis and Prevention Dr. Jacob Korach - Deputy director Gynecologic Oncology (past chair - Israeli Society of Gynecologic Oncology) Prof. Eitan Friedman - Head, Oncogenetics
More information